Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Free Cash Flow (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Free Cash Flow for 12 consecutive years, with -$3.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 32.72% year-over-year to -$3.3 million, compared with a TTM value of -$17.3 million through Sep 2025, up 8.68%, and an annual FY2024 reading of -$19.4 million, up 3.37% over the prior year.
  • Free Cash Flow was -$3.3 million for Q3 2025 at Lisata Therapeutics, up from -$4.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$2.5 million in Q3 2024 and bottomed at -$8.2 million in Q1 2023.
  • Average Free Cash Flow over 3 years is -$4.7 million, with a median of -$4.2 million recorded in 2023.
  • The sharpest move saw Free Cash Flow increased 29.72% in 2024, then crashed 32.72% in 2025.
  • Year by year, Free Cash Flow stood at -$4.1 million in 2023, then decreased by 11.28% to -$4.5 million in 2024, then rose by 26.19% to -$3.3 million in 2025.
  • Business Quant data shows Free Cash Flow for LSTA at -$3.3 million in Q3 2025, -$4.0 million in Q2 2025, and -$5.4 million in Q1 2025.